

REMARKS

Applicant, through the undersigned, wishes to thank Examiner Whiteman and Supervisory Examiner Burke for the courtesy and assistance extended on behalf of Applicant during a telephone interview conducted on March 31, 2005.

In the Final Action dated January 14, 2005, claims 16-30 are pending and under consideration. The Examiner has objected to the reissue declaration because the declaration does not state that all errors being corrected in the instant reissue declaration arose without deceptive intention. Claims 16-30 are objected to under 35 U.S.C. §251 as being based on a defective reissue declaration. The specification is objected to for allegedly failing to comply with the Sequence Rules. Claims 16-30 are objected to because of certain informalities.

This Response addresses each of the Examiner's objections and rejections. Accordingly, it is respectfully submitted that the present application is in condition for allowance. Favorable consideration of all pending claims is therefore respectfully requested.

Regarding the objection to the declaration, Applicant respectfully submits herewith a supplemental reissue declaration, which now states that all errors being corrected in the instant reissue declaration arose without deceptive intention on the part of Applicant. As such, withdrawal of the objection to the declaration and the rejection of claims 16-30 based on a defective declaration is therefore respectfully requested.

Regarding the objection to the specification, the Examiner states that the sequence that

recite that "Figure 2A and Figure 2B, joined at the match line", depict the double-stranded nucleotide sequence of SEQ ID NO: 2. As such, the objection to the specification is overcome. Withdrawal of the objection is respectfully requested.


Regarding the objection to the format of claims 16-30, the Examiner states that for each new claim added to the reissue application by the amendment being submitted, the entire text of the added claim must be completely underlined.

Accordingly, Applicant has represented the amendments to the claims, relative to the patent claims, in the format required under 37 C.F.R. §1.173. Furthermore, Applicant has presented in accordance with the provisions of 37 C.F.R. §1.173(c), on a separate page, the status of all patent claims and all added claims, as well as support for the changes made relative to the patent claims. Thus, the objection to the format of the claims is overcome. Withdrawal of the objection is therefore respectfully requested. Applicant is also providing a courtesy copy of the marked up version of the present claims, showing the changes made relative to the claims presented in the Preliminary Amendment dated July 16, 2003.

During the interview on March 31, 2005, the Examiner has also requested that Applicant explain the term, "a non-biologically functionally protein", as recited in claim 20. Applicant respectfully directs the Examiner's attention to col. 7, lines 15-19 of the specification, where non-biologically functionally proteins are described. Applicant respectfully submits that in light of the specification, the term is clear to those skilled in the

In view of the foregoing amendments and remarks, it is firmly believed that the subject application is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,


Kenneth L. Cage
Registration No. 26,151

McDermott, Will & Emery
600 13th Street, N.W.
Washington, D.C. 20005-3096
Tel: (202) 756-8363
Date: June 14, 2005
Enc.: Supplemental Declaration